M. Hallek

Molecular Biology · 2001–2021

A researcher in the Science corpus: 20 papers; trusts 12 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

Whom M. Hallek trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. G. Semenza
  2. H.A. Bischoff-Ferrari
  3. J. Magaziner
  4. N. Mottet
  5. P. Walsh
  6. Celestia S. Higano
  7. W. Willett
  8. J. Bellmunt
  9. J. D. de Bono
  10. John B. Wong

Who trusts M. Hallek overall

  1. Prashanth Rawla
  2. Hao Chen

Papers from M. Hallek's perspective

Ordered by how strongly the researchers M. Hallek trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy (New England Journal of Medicine)
  2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (New England Journal of Medicine)
  3. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. (New England Journal of Medicine)
  4. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. (The Lancet)
  5. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer (New England Journal of Medicine)
  6. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy (New England Journal of Medicine)
  7. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. (Journal of Clinical Oncology)
  8. Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer (New England Journal of Medicine)
  9. Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. (Journal of Urology)
  10. Radical prostatectomy versus watchful waiting in early prostate cancer. (Journal of Urology)

Their papers